Nasdaq-listed CEA Industries is facing growing pressure from one of its most prominent investors, as Changpeng Zhao-backed YZi Labs publicly criticized the company’s recent governance moves, deepening a boardroom dispute that has unfolded rapidly over the past month.
In a post shared Wednesday on X, YZi Labs condemned CEA Industries for adopting what it described as “stockholder-unfriendly” measures, including a limited-duration stockholder rights plan, commonly known as a poison pill, alongside amendments to the company’s bylaws. According to YZi, the changes are designed to entrench the current board and restrict shareholders’ ability to act by written consent.
— YZi Labs (@yzilabs) January 7, 2026
The public clash marks a sharp reversal from the optimism that surrounded the relationship just five months ago. In July, CEA Industries announced a $500 million private investment in public equity (PIPE) led by YZi Labs and 10X Capital, alongside a strategic pivot away from vape manufacturing toward a crypto-focused treasury strategy centered on BNB. The move triggered a surge of roughly 600% in CEA’s stock at the time.
From partnership to power struggle
Tensions surfaced last month when YZi Labs made regulatory filings outlining an aggressive campaign to reshape CEA’s board. The proposal included expanding the board, reversing recent bylaw changes, and installing a new slate of directors through a written-consent process. YZi later disclosed plans to form a coordinated shareholder group, signaling its intent to increase its ownership stake.
YZi has argued that CEA’s performance since the PIPE transaction has failed to reflect the company’s stated strategy. While BNB, CEA’s primary treasury asset, has risen by roughly 38% over the past six months, CEA’s stock has declined nearly 37% over the same period. The investment firm has pointed to this divergence as evidence of weak execution and governance concerns.
The poison pill explained
In response to YZi’s actions, CEA Industries’ board adopted a stockholder rights plan and amended its bylaws. Under the poison pill, if any individual or group acquires 15% or more of the company’s outstanding shares without board approval, other shareholders gain the right to purchase additional shares at a 50% discount. This mechanism would significantly dilute the acquiring party’s stake, making a hostile takeover far more expensive.
CEA Industries Inc.Such defenses are not uncommon among public companies facing activist pressure. Boards often argue that poison pills protect long-term shareholder value by preventing abrupt or coercive takeovers. Critics, however, contend that they can also be used to shield incumbent management from accountability.
YZi Labs falls firmly in the latter camp. In its statement, the firm said it was “disappointed” by CEA’s actions and accused the board of deliberately attempting to block shareholders from exercising their rights.
Strategic concerns add fuel
Beyond governance, YZi raised concerns about CEA’s strategic direction. The firm said comments made by CEO David Namdar about potentially shifting the company’s treasury strategy toward other crypto assets, including Solana, unsettled investors who backed CEA specifically for its focus on BNB.
YZi also criticized the company for delaying its 2025 annual meeting beyond its Dec. 17 anniversary date and warned against what it described as possible “manipulative behavior” related to meeting scheduling or director nominations.
In a message, Ella Zhang, head of YZi Labs, said the firm remains open to dialogue but firm in its position.
“YZi will remain committed to constructive dialogs, protecting the shareholders’ interest and promoting the integrity and value of the BNB ecosystem,” she said.
CEA Industries has not yet publicly responded to the latest criticism.
Market reaction
CEA Industries (ticker: BNC) closed up 1.56% at $6.51 on Tuesday. Despite the modest daily gain, the stock’s longer-term performance continues to lag its core crypto asset, underscoring the gap that has become central to the dispute.
